Valuing the cost of improving Chilean primary vaccination: A cost minimization analysis of a hexavalent vaccine

Ignacio Olivera, Carlos Grau, Hugo Dibarboure, Juan Pablo Torres, Gustavo Mieres, Luis Lazarov, Fabián P. Alvarez, Juan Guillermo López Yescas

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio 'end-game' strategy. Methods: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). Results: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. Conclusions: The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.

Original languageEnglish
Article number295
JournalBMC Health Services Research
Issue number1
StatePublished - 9 Apr 2020
Externally publishedYes


  • Cost
  • Pediatric
  • Polio
  • Vaccination


Dive into the research topics of 'Valuing the cost of improving Chilean primary vaccination: A cost minimization analysis of a hexavalent vaccine'. Together they form a unique fingerprint.

Cite this